Evaluation of an Edible Polyherbal Formulation against Urinary Tract Infection Pathogens, its Antioxidant and Anti Inflammatory Potential

Author(s):  
Zuvairiya Abbas ◽  
Ashwini Lydia Manoharan ◽  
Gayathri Jagadeesan ◽  
Gayathri Nataraj ◽  
Kasipandi Muniyandi ◽  
...  
PEDIATRICS ◽  
1994 ◽  
Vol 93 (4) ◽  
pp. 693-693
Author(s):  
Ahmad Wattad ◽  
Tammy Feehan ◽  
Frank M. Shepard ◽  
George Youngberg

We read with great interest the two case reports by McIntire et al 1 on "Acute Flank Pain and Reversible Renal Dysfunction Associated with Nonsteroidal Anti-Inflammatory Drug Use." We also treated a 14-year-old healthy girl who had acute severe bilateral flank pain and nonoliguric acute renal failure. The patient's flank pain and vomiting started 4 days before admission. A diagnosis of possible urinary tract infection was made and amoxicillin therapy was instituted. Her past medical history was unremarkable except for an uncomplicated urinary tract infection 6 years earlier.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Albert Macaire C. Ong Lopez ◽  
Charles Jeffrey L. Tan ◽  
Antonio S. Yabon ◽  
Armin N. Masbang

Abstract Background Current guidelines recommend empiric antibiotics as first-line treatment for uncomplicated UTI. Despite proven benefits in treatment, antibiotic resistance rates remain on the rise. This meta-analysis aims to determine whether non-steroidal anti-inflammatory drugs can serve as an effective and safe option in the treatment of uncomplicated lower UTI among non-pregnant women compared to antibiotics. Methods A systematic literature search in PUBMED, CENTRAL, and ACP databases from inception to April 2021 was conducted to identify randomized controlled trials that compare the use of non-steroidal anti-inflammatory drugs versus antibiotics in non-pregnant women ≥18 years old with uncomplicated lower urinary tract infection. Primary outcomes were symptom resolution of UTI by Day 3 or 4 of intervention, and upper UTI complications. Secondary outcomes include persistence of positive urine culture despite treatment and need for another rescue antibiotic. Random and fixed-effects model for dichotomous data using Mantel-Haenszel and Peto odds method were reported at 95% CI followed by sensitivity analysis for substantial heterogeneity. Results Four RCTs involving 1165 patients were analyzed. The probability of having a symptom resolution by Day 3 or 4 with NSAID use is only less than three-fourths of that with antibiotic treatment (RR: 0.69, 95% CIs [0.55, 0.86], p = 0.0008, I2 = 73%, moderate certainty of evidence). The odds of developing upper UTI complications with use of NSAIDs are 6.49 to 1 for antibiotics (Peto OR: 6.49, 95% CIs [3.02, 13.92], p < 0.00001, I2 = 0%, moderate certainty of evidence). Secondary analysis showed that the NSAID group is 2.77x more likely to have persistence of a positive microbiologic urine culture than the antibiotic group (RR: 2.77, 95% CIs [1.95, 3.94], p < 0.00001, I2 = 36%, moderate certainty of evidence). Treatment with NSAIDs are three times more likely to use a secondary or rescue antibiotic due to persistent or worsening symptoms as compared to antibiotics (RR: 3.16, 95% CIs [2.24, 4.44], p < 0.00001, I2 = 47%, low certainty of evidence). Conclusion Antibiotic treatment was more effective than use of non-steroidal anti-inflammatory drugs for acute uncomplicated lower urinary tract infection with an overall moderate certainty of evidence.


2016 ◽  
Vol 10 (34) ◽  
pp. 1408-1416 ◽  
Author(s):  
Farouk Ahmed Eman ◽  
Mahmoud Abd El-Baky Rehab ◽  
Bakr F Ahmed Abo ◽  
Gameel Fawzy Nancy ◽  
Abdel Aziz Neveen ◽  
...  

2000 ◽  
Vol 68 (10) ◽  
pp. 5816-5823 ◽  
Author(s):  
Liliana A. Håversen ◽  
Inga Engberg ◽  
Lars Baltzer ◽  
Gunnar Dolphin ◽  
Lars Å. Hanson ◽  
...  

ABSTRACT Lactoferrin (LF) is a multifunctional immunoregulatory protein that has been associated with host defense at mucosal surfaces through its antibacterial properties. The antibacterial and anti-inflammatory properties of LF were further explored with an animal model of experimental urinary tract infection. Bovine LF (bLF), human LF (hLF), and synthetic peptide sequences based on the antibacterial region of hLF (amino acid residues 16 to 40 [HLD1] and 18 to 40 [HLD2]) were given orally to female mice 30 min after the instillation of 108 Escherichia coli bacteria into the urinary bladder. The control groups received phosphate-buffered saline or water. C3H/Tif mice were treated with hLF or bLF, and C3H/HeN mice were treated with bLF only. The numbers of bacteria in the kidneys and bladder of C3H/Tif and C3H/HeN mice were significantly reduced 24 h later by the LF treatments compared to the findings for the control group. The hLF-treated group showed the strongest reduction compared with the vehicle-treated-group (P values were 0.009 and 0.0001 for the kidneys and bladder, respectively). The urinary leukocyte response was diminished in the hLF-treated group. The hLF treatment also significantly reduced the urinary interleukin-6 (IL-6) levels at 2 h and the systemic IL-6 levels at 24 h after infection (P values were 0.04 and < 0.002, respectively). In the bLF-treated animals, no such strong anti-inflammatory effects were obtained. In another series of experiments, C3H/Tif mice perorally treated with HLD1 or HLD2 also showed reduced numbers of bacteria in the kidneys compared with the vehicle-treated mice, although the results were significantly different only for HLD2 (P < 0.01). Analysis of urine from hLF-fed C3H/Tif mice showed that hLF was excreted into the urinary tract at 2 h after feeding. Testing of the in vitro bactericidal activity of LF (1 mg/ml) or the peptides (0.1 mg/ml) in mouse urine against the E. coli bacteria revealed moderate killing only by HLD2. In conclusion, these results demonstrate for the first time that oral administration of hLF or peptides thereof is effective in reducing infection and inflammation at a remote site, the urinary tract, possibly through transfer of hLF or its peptides to the site of infection via renal secretion. The antibacterial mechanism is suggested to involve bactericidal capacities of LF, fragments thereof, or its peptides.


2004 ◽  
Vol 171 (4S) ◽  
pp. 22-23
Author(s):  
Shingo Minagawa ◽  
Chikara Ohyama ◽  
Shingo Hatakeyama ◽  
Kazunari Sato ◽  
Shigeru Sato ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document